IL-22 is clinically relevant in AD, as demonstrated by a phase II clinical trial in which treatment with an anti–IL-22 monoclonal antibody led to significant improvement in adults with moderate-to-severe chronic AD, particularly in those with high baseline IL-22 expression (2). The gene discussed is IL22; the disease is Alzheimer disease.